Payment overview · 2025
General Payments
$878.67
40 reported records · 10 companies
Healthcare provider profile · identity verified
Craig A Dolven, DO
Allopathic & Osteopathic Physicians|Family Medicine · ORANGE PARK, FL · NPI 1962504787
Verified facts
What the public records show
CMS Open Payments records show Craig A Dolven, DO received $878.67 in general payments during 2025 across 40 reported records.
Novo Nordisk Inc accounted for 27.1% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 20 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Jardiance, Mounjaro, Ozempic, Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 31 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 63 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 31 claims for Symbicort by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 47 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 54 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 56 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 30 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 230 claims for Ozempic by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $238.56 | 27.1% | 8 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $178.90 | 20.4% | 9 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $146.19 | 16.6% | 7 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $103.60 | 11.8% | 6 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $93.16 | 10.6% | 4 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $38.93 | 4.4% | 2 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $24.76 | 2.8% | 1 | 2025 |
| Inspire Medical Systems, Inc. | Unresolved — no canonical attribution shown | $20.74 | 2.4% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $20.06 | 2.3% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $13.77 | 1.6% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $878.67 | 40 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $214.08 | 6 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $113.71 | 6 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $103.60 | 6 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $93.16 | 4 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $64.27 | 2 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $63.28 | 4 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $53.92 | 3 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $38.93 | 2 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $36.55 | 2 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Lilly USA, LLC | $32.48 | 1 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $24.76 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $24.48 | 2 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $24.48 | 2 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $24.07 | 1 | 2025 |
Source payment records
|
|||||
| INSPIRE Normalized: inspire |
Device | Inspire Medical Systems, Inc. | $20.74 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $20.06 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $20.06 | 1 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $14.86 | 1 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $13.77 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $13.77 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 63 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 54 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 56 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 230 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 47 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
31 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
63 | 17 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
31 | 13 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
47 | 16 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
54 | 17 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
56 | 12 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
30 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
230 | 60 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 1065 | 346 |
| Amlodipine Besylate | Amlodipine Besylate | 615 | 197 |
| Lisinopril | Lisinopril | 491 | 157 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 430 | 141 |
| Omeprazole | Omeprazole | 427 | 148 |
| Levothyroxine Sodium | Levothyroxine Sodium | 415 | 123 |
| Tamsulosin Hcl | Tamsulosin Hcl | 337 | 105 |
| Losartan Potassium | Losartan Potassium | 307 | 98 |
| Metformin Hcl | Metformin Hcl | 298 | 115 |
| Montelukast Sodium | Montelukast Sodium | 292 | 113 |
| Metoprolol Succinate | Metoprolol Succinate | 277 | 94 |
| Gabapentin | Gabapentin | 244 | 97 |
| Ozempic | Semaglutide | 230 | 60 |
| Fluoxetine Hcl | Fluoxetine Hcl | 194 | 62 |
| Metformin Hcl Er | Metformin Hcl | 175 | 55 |
| Trazodone Hcl | Trazodone Hcl | 174 | 70 |
| Allopurinol | Allopurinol | 161 | 54 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 158 | 64 |
| Pantoprazole Sodium | Pantoprazole Sodium | 157 | 53 |
| Hydrochlorothiazide | Hydrochlorothiazide | 146 | 52 |
| Meloxicam | Meloxicam | 143 | 56 |
| Metoprolol Tartrate | Metoprolol Tartrate | 141 | 51 |
| Eliquis | Apixaban | 140 | 33 |
| Carvedilol | Carvedilol | 129 | 46 |
| Alendronate Sodium | Alendronate Sodium | 112 | 35 |
| Clopidogrel | Clopidogrel Bisulfate | 111 | 33 |
| Pioglitazone Hcl | Pioglitazone Hcl | 102 | 33 |
| Famotidine | Famotidine | 98 | 34 |
| Fluticasone Propionate | Fluticasone Propionate | 92 | 35 |
| Sertraline Hcl | Sertraline Hcl | 92 | 29 |
| Potassium Chloride | Potassium Chloride | 86 | 25 |
| Furosemide | Furosemide | 82 | 31 |
| Prednisone | Prednisone | 82 | 64 |
| Glipizide Er | Glipizide | 80 | 25 |
| Simvastatin | Simvastatin | 70 | 27 |
| Doxycycline Hyclate | Doxycycline Hyclate | 69 | 57 |
| Mirtazapine | Mirtazapine | 69 | 23 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 66 | 22 |
| Farxiga | Dapagliflozin Propanediol | 63 | 17 |
| Doxepin Hcl | Doxepin Hcl | 62 | 17 |
| Ropinirole Hcl | Ropinirole Hcl | 61 | 18 |
| Atenolol | Atenolol | 60 | 22 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 58 | 19 |
| Pravastatin Sodium | Pravastatin Sodium | 57 | 15 |
| Amitriptyline Hcl | Amitriptyline Hcl | 56 | 21 |
| Mounjaro | Tirzepatide | 56 | 12 |
| Escitalopram Oxalate | Escitalopram Oxalate | 55 | 15 |
| Ibuprofen | Ibuprofen | 54 | 27 |
| Jardiance | Empagliflozin | 54 | 17 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 53 | 21 |
| Ezetimibe | Ezetimibe | 52 | 16 |
| Hydralazine Hcl | Hydralazine Hcl | 52 | 19 |
| Duloxetine Hcl | Duloxetine Hcl | 48 | 13 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 47 | 17 |
| Spironolactone | Spironolactone | 47 | 15 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 47 | 16 |
| Oxybutynin Chloride | Oxybutynin Chloride | 46 | 15 |
| Methylprednisolone | Methylprednisolone | 45 | 44 |
| Citalopram Hbr | Citalopram Hydrobromide | 44 | 14 |
| Finasteride | Finasteride | 44 | 15 |
| Ondansetron Hcl | Ondansetron Hcl | 44 | 19 |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 44 | 23 |
| Bupropion Xl | Bupropion Hcl | 42 | 16 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 37 | 20 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 37 | 28 |
| Tizanidine Hcl | Tizanidine Hcl | 33 | 18 |
| Cefdinir | Cefdinir | 32 | 29 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 32 | 17 |
| Terazosin Hcl | Terazosin Hcl | 32 | suppressed |
| Valsartan | Valsartan | 32 | suppressed |
| Baclofen | Baclofen | 31 | suppressed |
| Memantine Hcl | Memantine Hcl | 31 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 31 | suppressed |
| Repaglinide | Repaglinide | 31 | 13 |
| Symbicort | Budesonide/Formoterol Fumarate | 31 | 13 |
| Synthroid | Levothyroxine Sodium | 31 | suppressed |
| Acyclovir | Acyclovir | 30 | 11 |
| Glimepiride | Glimepiride | 30 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 30 | 13 |
| Paroxetine Hcl | Paroxetine Hcl | 30 | suppressed |
| Trulicity | Dulaglutide | 30 | suppressed |
| Nifedipine Er | Nifedipine | 29 | 11 |
| Primidone | Primidone | 29 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 28 | 11 |
| Cholestyramine | Cholestyramine (With Sugar) | 28 | 13 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 28 | 18 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 28 | suppressed |
| Celecoxib | Celecoxib | 27 | suppressed |
| Lorazepam | Lorazepam | 27 | suppressed |
| Spironolactone-Hctz | Spironolact/Hydrochlorothiazid | 27 | suppressed |
| Estradiol | Estradiol | 26 | 13 |
| Ketoconazole | Ketoconazole | 26 | 11 |
| Naproxen | Naproxen | 26 | 16 |
| Paxlovid | Nirmatrelvir/Ritonavir | 26 | 25 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 25 | 22 |
| Diclofenac Sodium | Diclofenac Sodium | 25 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 25 | suppressed |
| Fluconazole | Fluconazole | 25 | 15 |
| Torsemide | Torsemide | 25 | suppressed |
| Verapamil Er | Verapamil Hcl | 25 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 24 | suppressed |
| Methocarbamol | Methocarbamol | 24 | 15 |
| Propranolol Hcl | Propranolol Hcl | 24 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 24 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 23 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 22 | suppressed |
| Glipizide | Glipizide | 22 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 22 | 19 |
| Clonazepam | Clonazepam | 21 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 21 | 15 |
| Fenofibrate | Fenofibrate,micronized | 21 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 21 | suppressed |
| Bumetanide | Bumetanide | 20 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 19 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 19 | suppressed |
| Amoxicillin | Amoxicillin | 18 | 16 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 18 | suppressed |
| Irbesartan | Irbesartan | 18 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 18 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 18 | suppressed |
| Alprazolam | Alprazolam | 17 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 17 | suppressed |
| Chlorthalidone | Chlorthalidone | 17 | suppressed |
| Cilostazol | Cilostazol | 17 | suppressed |
| Pregabalin | Pregabalin | 17 | suppressed |
| Ramipril | Ramipril | 17 | suppressed |
| Risperidone | Risperidone | 17 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 16 | suppressed |
| Cephalexin | Cephalexin | 16 | 14 |
| Labetalol Hcl | Labetalol Hcl | 16 | suppressed |
| Lactulose | Lactulose | 16 | suppressed |
| Myrbetriq | Mirabegron | 16 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 16 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 15 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 15 | suppressed |
| Epinephrine | Epinephrine | 15 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 15 | suppressed |
| Neomycin-Polymyxin-Hydrocort | Neomycin/Polymyxin B/Hydrocort | 15 | 12 |
| Topiramate | Topiramate | 15 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 14 | suppressed |
| Dutasteride | Dutasteride | 14 | suppressed |
| Levetiracetam | Levetiracetam | 14 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 14 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 14 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 13 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 13 | suppressed |
| Klor-Con 10 | Potassium Chloride | 13 | suppressed |
| Lansoprazole | Lansoprazole | 13 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 13 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 13 | suppressed |
| Colchicine | Colchicine | 12 | suppressed |
| Eszopiclone | Eszopiclone | 12 | suppressed |
| Januvia | Sitagliptin Phosphate | 12 | suppressed |
| Ofloxacin | Ofloxacin | 12 | suppressed |
| Clindamycin Phosphate | Clindamycin Phosphate | 11 | suppressed |
| Colestipol Hcl | Colestipol Hcl | 11 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 11 | suppressed |
| Juluca | Dolutegravir/Rilpivirine | 11 | suppressed |
| Neomycin-Polymyxin-Hc | Neomycin/Polymyxin B/Hydrocort | 11 | suppressed |
| Spiriva Handihaler | Tiotropium Bromide | 11 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 11 | suppressed |
| Xarelto | Rivaroxaban | 11 | suppressed |
| Zolpidem Tartrate Er | Zolpidem Tartrate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $878.67 · 40 records | Novo Nordisk Inc | AIRSUPRA, AREXVY, BREZTRI, Cologuard Collection Kit, FARXIGA, INSPIRE, JARDIANCE, Kerendia, MOUNJARO, OTEZLA, Ozempic, QULIPTA, REPATHA, Rybelsus, SHINGRIX, TRELEGY ELLIPTA, UBRELVY, VOQUEZNA, Wegovy, ZEPBOUND | 8 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error